What it is
Insulin-like growth factor 1 (IGF-1) is a natural human protein of 70 amino acids (the building blocks of proteins). The liver makes most of the IGF-1 in the blood, prompted by growth hormone from the pituitary gland, and many other tissues make their own for local use. IGF-1 is the main messenger through which growth hormone drives growth in childhood, and in adults it keeps an anabolic (tissue-building) effect. Its receptor sits on almost every cell. Almost none of it floats free: about 98% is carried bound to a family of six IGF-binding proteins, which both protect it and keep it from reaching receptors.
More on what it is and where it came from
IGF-1 LR3 is a man-made variant of that protein. It carries two changes. First, the amino acid at position 3 is swapped from glutamate to arginine. Second, a 13-amino-acid tail is added to the front end, built from the first 11 amino acids of pig growth hormone plus two more. Both changes together make the molecule bind the IGF-binding proteins far more weakly, so a much greater share of it stays free and able to reach receptors. In rat plasma the difference in binding is roughly a thousandfold. Because the extension adds 13 residues to the 70 of IGF-1, the analogue is 83 amino acids long.
It is not a medicine and was never designed as one. It was created in an Adelaide laboratory as a research tool for studying how the binding proteins control IGF-1, and it went on to be used widely as a cell-culture ingredient: companies that grow animal cells to manufacture protein drugs add it in place of insulin. Products sold online under this name are the same reagent or something close to it. When the Cologne anti-doping laboratory analysed seized black-market products in 2009 it reported finding unpurified long-R3-IGF-1, and in a separate case a vial contained a research-grade version carrying a six-histidine purification tag, a form made for laboratory handling rather than for injecting into anyone.
The molecule came out of a group in Adelaide, South Australia, in the early 1990s: the CSIRO Division of Human Nutrition, the Child Health Research Institute and the Cooperative Research Centre for Tissue Growth and Repair, in work led by Francis, Ballard, Tomas, Read, Wallace and colleagues. Francis and co-workers reported in 1992 an efficient bacterial system that made IGF-I with an N-terminal extension, in three forms: the plain extended protein (Long IGF-I) and two with position 3 changed, to glycine or to arginine. The arginine form, Long [Arg3]-IGF-I, is what is now sold as IGF-1 LR3. The group's stated purpose was to work out how much of IGF-I's activity is controlled by the binding proteins rather than by the receptor, and the extension also turned out to help the protein fold correctly, which made it easier to manufacture. The same group then ran the rat studies that most of the evidence still rests on.
How it is thought to work
In cell and animal work the analogue appears to act through the same receptor as IGF-1, but to reach it more easily. Francis and colleagues reported in 1992 that in cell lines which secrete IGF-binding proteins, the extended arginine-3 form was more potent than IGF-I at stimulating protein and DNA synthesis and at slowing protein breakdown. In chicken embryo fibroblasts, which secrete no detectable binding proteins, it was actually less potent than IGF-I. The same paper found it binds the type 1 IGF receptor somewhat less well than IGF-I does. The extra potency therefore seems to come from escaping the binding proteins, not from a better fit at the receptor.
More on how it works
Ballard and colleagues reported in 1993 that IGF-I binds IGFBP-3, IGFBP-4, whole rat plasma binding proteins and the binding protein made by L6 muscle cells with about a thousandfold higher affinity than the LR3 analogue. In cultured L6 myoblasts that weaker binding translated into 5 to 10 times the potency of IGF-I, and in growing rats about 6 times the potency.
A consequence that is often reported the wrong way round online is clearance. Because the binding proteins act as a reservoir, the analogue is removed from the blood much faster than IGF-I, not more slowly. Bastian and colleagues measured this directly in rats with radioactively labelled peptide: the analogue was cleared roughly ten times faster than IGF-I in ordinary rats, and most of it circulated as free peptide rather than bound. In pregnant rats, which naturally have much less IGFBP-3, IGF-I's own clearance sped up until it approached the analogue's. A 2021 review of IGF-1 states the opposite, that the analogue has a considerably longer half-life; that conflict is recorded in the open questions below.
What is established in people
There is none. No published human trial of IGF-1 LR3 was found in PubMed, and ClinicalTrials.gov returned no registered study of it under any of its names. A 2021 anti-doping paper states that these IGF-I analogues have never been approved for human use. The only human exposure described anywhere in the literature opened for this page is unmeasured and uncontrolled: anti-doping laboratories reporting the substance in seized black-market products, in one case unpurified and in another carrying a laboratory purification tag. The whole evidence base is cells, rats, pigs, marmosets, cattle and mice, mostly from one Adelaide group in the 1990s, mostly over a week or two, and mostly measuring growth and nitrogen balance rather than anything a person would notice. A different molecule, plain recombinant human IGF-1 (mecasermin, Increlex), has been an approved medicine since 2005 for one rare childhood growth disorder, and its label is the best available guide to what raising IGF-1 signalling does in people; it is not evidence about this analogue.
What the studies found
13 studies, human trials first. Each links to the paper or registry record.
- Review2010
Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies.
Women in the highest fifth of natural IGF-1 levels had a 28% higher odds of breast cancer than those in the lowest fifth (odds ratio 1.28, 95% confidence interval 1.14 to 1.44).
Full finding, who was studied, and limits
Who: Pooled individual data from 17 prospective studies in 12 countries: 4,790 women who developed breast cancer and 9,428 matched women who did not. Blood was taken before any cancer was diagnosed.
Women in the highest fifth of natural IGF-1 levels had a 28% higher odds of breast cancer than those in the lowest fifth (odds ratio 1.28, 95% confidence interval 1.14 to 1.44). Adjusting for IGFBP3 did not change this. The association was confined to oestrogen-receptor-positive tumours (odds ratio 1.38, 1.14 to 1.68) and was absent for receptor-negative tumours (0.80, 0.57 to 1.13).
Read with care: This is an association between people's own natural IGF-1 levels and later cancer. It is not a study of anyone given IGF-1 or an analogue, and it does not show that raising IGF-1 causes cancer. The effect is modest. It is included because it is the main reason researchers treat raised IGF-1 signalling as a theoretical cancer concern.
- Review1993
Effects of interactions between IGFBPs and IGFs on the plasma clearance and in vivo biological activities of IGFs and IGF analogs.
IGF-I binds IGFBP-3, IGFBP-4, the total binding proteins in rat plasma and the L6 myoblast binding protein with roughly a thousandfold greater affinity than the LR3 analogue.
Full finding, who was studied, and limits
Who: A summary by the Adelaide group of their own binding measurements, rat growth studies and clearance studies.
IGF-I binds IGFBP-3, IGFBP-4, the total binding proteins in rat plasma and the L6 myoblast binding protein with roughly a thousandfold greater affinity than the LR3 analogue. That weaker binding gave the analogue 5 to 10 times the potency of IGF-I in cultured L6 myoblasts and about 6 times the potency in 14-day growth studies in normal female rats. In the same work the analogue was cleared from the blood much faster than IGF-I. Pregnant rats, which have much lower binding protein levels, confirmed the mechanism: in them IGF-I's own clearance became nearly as fast as the analogue's.
Read with care: A short review by the molecule's developers, summarising their own data. The thousandfold figure is for rat plasma; binding differs markedly between species, and in sheep, human, pig and chicken plasma these variants bind noticeably more than they do in rat plasma.
- Animal study2025
Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice.
This is the longest treatment study found in any animal, and it is a negative one on the outcome that mattered.
Full finding, who was studied, and limits
Who: Male 5XFAD mice, a strain bred to develop Alzheimer's-like brain changes, and normal control mice, given the LR3 analogue or vehicle into the nose for seven months, from 3 to 10 months of age. Plus BV-2 microglial cells in culture. Group sizes are not given in the abstract.
This is the longest treatment study found in any animal, and it is a negative one on the outcome that mattered. Treated mice had better body composition, but tests of learning and memory did not improve significantly. In the brain's cortex the treatment reduced filamentous amyloid plaques, increased inert plaques and lowered small amyloid-beta clusters. In cultured microglia it increased uptake of amyloid-beta. The authors concluded it does not look suitable on its own and would need to be studied in combination.
Read with care: Mice, male only, one strain, a disease model that does not reproduce human Alzheimer's disease. The headline finding is that the biological changes did not translate into better function. Nothing in it is evidence for muscle, performance or recovery claims.
- Animal study2021
Detection of LongR(3)-IGF-I, Des(1-3)-IGF-I, and R(3)-IGF-I using immunopurification and high resolution mass spectrometry for antidoping purposes.
The authors state plainly that these analogues are prohibited in sport, have never been approved for human use, and are sold on the black market for bodybuilding.
Full finding, who was studied, and limits
Who: Rats given a single intramuscular injection, plus the analogues incubated in human whole blood in the laboratory, and black-market products analysed. French anti-doping laboratory and partners.
The authors state plainly that these analogues are prohibited in sport, have never been approved for human use, and are sold on the black market for bodybuilding. They built a detection method using an anti-IGF-I antibody capture followed by high-resolution mass spectrometry. Black-market products often contained oxidised forms of the peptide, so the authors recommend testing for both the native and the single-oxidised form. In rats, intact des(1-3)-IGF-I and R3-IGF-I could be found for up to 24 hours, but LongR3-IGF-I itself disappeared within about 4 hours. Breakdown products missing the first residue, the first ten and the first eleven residues were identified, the last detectable for up to 16 hours. The same breakdown products formed in human blood in the dish, which the authors say suggests the findings carry over to people.
Read with care: A detection study, not a study of effect or safety. The human part was blood in a test tube, not a person given the peptide. Doses are recorded only in trialDoseNotes.
- Animal study1999
Action of long(R3)-insulin-like growth factor-1 on protein metabolism in beef heifers.
This is the clearest livestock study found.
Full finding, who was studied, and limits
Who: Beef heifers losing weight on a restricted, low-quality diet, given an 8-hour intravenous infusion of the LR3 analogue, with a control group. Group sizes are not given in the abstract. Queensland Beef Industry Institute.
This is the clearest livestock study found. Whole-body and skeletal muscle protein tended to be conserved in the treated heifers. The infusion sharply lowered plasma levels of all measured amino acids and of glucose. The animals' own IGF-1 fell steeply during the infusion, and plasma IGF-2 fell much further in the treated group (about 140 ng/ml) than in controls (about 40 ng/ml). A binding protein of 31 to 32 kDa, possibly IGFBP-1, was higher in treated animals. The authors suggested it be explored as a way to reduce weight loss in the dry season.
Read with care: Eight hours, in cattle, on a restricted diet, with 'tended to' rather than a clear statistically significant protein-sparing result. The fall in the animals' own IGF-1 and IGF-2 during treatment is a reminder that giving a growth factor shifts the whole system, not just one number.
- Animal study1997
IGF-I variants which bind poorly to IGF-binding proteins show more potent and prolonged hypoglycaemic action.
Blood sugar fell in proportion to the amount given, with maximum falls of 4.8 mmol/L in pigs, 3.7 mmol/L in conscious marmosets and 2.5 mmol/L in anaesthetised marmosets.
Full finding, who was studied, and limits
Who: Pigs given IGF-I, des(1-3)IGF-I, long IGF-I, R3IGF-I or the LR3 analogue as single injections, with insulin for comparison; and marmoset monkeys given IGF-I or des(1-3)IGF-I. Blood sampled from half an hour before to 4 hours after. Group sizes are not given in the abstract.
Blood sugar fell in proportion to the amount given, with maximum falls of 4.8 mmol/L in pigs, 3.7 mmol/L in conscious marmosets and 2.5 mmol/L in anaesthetised marmosets. The variants that bind the binding proteins poorly were 2 to 3 times more potent than IGF-I at the lowest point, and over four hours produced roughly 4 to 8 times more total blood-sugar suppression. Potency tracked binding affinity, ranking IGF-I lowest, then long IGF-I, then R3IGF-I and the LR3 analogue, then des(1-3)IGF-I. Blood amino acids fell in the pigs, and of all the peptides only the LR3 analogue was more potent than IGF-I on that measure.
Read with care: Animals, single injections, a few hours of observation. It is the most directly relevant hazard study available, but it was not designed as a safety study and nothing equivalent has been published in people. Doses are recorded only in trialDoseNotes.
- Animal study1993
Insulin-like growth factor-I and more potent variants restore growth of diabetic rats without inducing all characteristic insulin effects.
All treatments increased growth and nitrogen balance in proportion to the amount given.
Full finding, who was studied, and limits
Who: Rats of about 160 g made diabetic with streptozotocin, infused by mini-osmotic pump for 7 days, with vehicle and insulin groups for comparison. Group sizes are not given in the abstract.
All treatments increased growth and nitrogen balance in proportion to the amount given. The highest IGF-I treatment added 48.1 g over 7 days against 11.0 g in vehicle controls. The two variants that bind the binding proteins poorly, including the LR3 analogue, were 2.5 to 3 times more potent than IGF-I at restoring growth. Insulin produced the largest weight gain, 64.5 g, but the surplus was fat, not protein: 92.5 g of fat per kg of carcass against 32.2 in every other group. All the peptides raised muscle protein synthesis and RNA by up to 50%. Unlike insulin, the IGF peptides left sugar in the urine unchanged.
Read with care: Rats with chemically induced diabetes, one week. The authors' own conclusion is the careful one: the IGFs restored growth but did not restore insulin's metabolic work in liver, muscle and fat. Doses are recorded only in trialDoseNotes.
- Animal study1993
Anabolic effects of insulin-like growth factor-I (IGF-I) and an IGF-I variant in normal female rats.
This is the key study in healthy animals.
Full finding, who was studied, and limits
Who: Growing normal (not diseased) female rats, treated for 14 days by implanted osmotic pump, with a human growth hormone group for comparison. Group sizes are not given in the abstract.
This is the key study in healthy animals. Weight gain, nitrogen retention and feed conversion efficiency all improved in proportion to the amount given, by 18 to 26% at the highest IGF-I treatment. The LR3 analogue was substantially more potent: about a sixth as much matched the highest IGF-I treatment. Organ weights and carcass composition largely kept the proportions the animals started with. Human growth hormone did not stimulate growth in these rats. Muscle protein synthesis and myofibrillar breakdown both rose slightly, and the authors noted that the gain in nitrogen retention could not be explained by the protein accretion those measures implied.
Read with care: Rats, two weeks, continuous pump delivery. The authors could not account for where the retained nitrogen went. Nothing here is a measure of strength, exercise performance or body composition in a person. Doses are recorded only in trialDoseNotes.
- Animal study1992
Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated rats.
Steroid-treated rats lost 19 g over 7 days while pair-fed controls gained 18 g.
Full finding, who was studied, and limits
Who: Male rats of about 150 g made catabolic (losing tissue) with the steroid dexamethasone, given IGF-I or variants continuously by implanted osmotic pumps for 7 days. Group sizes are not given in the abstract.
Steroid-treated rats lost 19 g over 7 days while pair-fed controls gained 18 g. The highest IGF-I treatment turned the loss into a 6 g gain and improved nitrogen retention. Two variants that bind the binding proteins poorly, des(1-3)IGF-I and the LR3 analogue, were about 2.5 times more potent than IGF-I. Muscle protein synthesis rose and a marker of muscle protein breakdown in urine fell. Gut weight rose by up to 45%. The extra carcass weight was nitrogen, not fat, and steroid-distorted liver, spleen and heart weights moved back toward normal. The authors noted the LR3 analogue achieved this despite binding the type 1 IGF receptor about three times less well than IGF-I.
Read with care: Rats, one week, in an artificial steroid-induced catabolic state, with the peptide delivered continuously by pump. Partial reversal of a drug-induced loss is not the same as building tissue in a healthy animal. Doses are recorded only in trialDoseNotes.
- Animal study1992
Insulin-like growth factor-I and its N-terminal modified analogues induce marked gut growth in dexamethasone-treated rats.
Gut weight rose in proportion to the amount given, by up to 60%, and gut weight as a share of body weight by up to 32%.
Full finding, who was studied, and limits
Who: Rats of about 150 g made catabolic with dexamethasone, treated for 7 days. Group sizes are not given in the abstract. Child Health Research Institute, North Adelaide.
Gut weight rose in proportion to the amount given, by up to 60%, and gut weight as a share of body weight by up to 32%. Every region responded, including stomach, small intestine and colon. The intestine grew thicker rather than longer: wet weight, protein and DNA per unit length all rose in both the lining and the muscle layer. Duodenal protein synthesis measured on day 7 did not rise. The two analogues that bind the binding proteins poorly, including the LR3 analogue, produced the same pattern but were several times more potent. The authors concluded the gut is among the most IGF-I-sensitive tissues.
Read with care: Rats under steroid treatment. Organ enlargement is a measured effect, not in itself a benefit; it is also the kind of growth that raises questions nobody has answered in people.
- Cell study2014
Transcriptome analyses of CHO cells with the next-generation microarray CHO41K: development and validation by analysing the influence of the growth stimulating substance IGF-1 substitute LongR(3).
The paper's own title calls LongR3 an 'IGF-1 substitute', which is how the biomanufacturing field describes it.
Full finding, who was studied, and limits
Who: CHO cells grown with and without the LongR3 supplement, analysed with a custom 41,304-probe microarray, in triplicate. Universität Bielefeld.
The paper's own title calls LongR3 an 'IGF-1 substitute', which is how the biomanufacturing field describes it. Adding it improved growth, delayed cell death and changed genes involved in building the cell's internal skeleton. The authors suggested that supplemented cells spend less effort maintaining a large cytoskeleton, which may let them divide faster.
Read with care: Gene activity in cultured cells. It confirms the reagent's industrial role and gives a hint at mechanism; it establishes nothing about safety or effect in a living body.
- Cell study2000
Effects of insulin and LongR(3) on serum-free Chinese hamster ovary cell cultures expressing two recombinant proteins.
This is a primary source for what the molecule is actually used for.
Full finding, who was studied, and limits
Who: Two Chinese hamster ovary (CHO) cell lines grown without serum, each making a recombinant cytokine receptor protein. Cell Sciences, Immunex Corporation, Seattle.
This is a primary source for what the molecule is actually used for. The authors compared insulin with the LongR3 analogue as the growth factor in serum-free CHO culture. One line grew without any growth factor; the other needed either insulin or LongR3 to grow at all. Both lines needed a growth factor for best protein production, and LongR3 maintained viability under production conditions better than insulin did. The authors concluded LongR3 was the preferred factor for both lines.
Read with care: An industrial cell-culture study. It says nothing about effects in an animal or a person; it is evidence about what the reagent is for.
- Cell study1992
Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency.
This is the paper that introduced the molecule.
Full finding, who was studied, and limits
Who: Rat L6 myoblasts, rat H35 hepatoma cells and chicken embryo fibroblasts in culture, plus receptor and binding-protein binding assays. CSIRO Division of Human Nutrition and the Cooperative Research Centre for Tissue Growth and Repair, Adelaide.
This is the paper that introduced the molecule. The authors built three IGF-I variants, each with an N-terminal extension made of the first 11 amino acids of methionyl pig growth hormone followed by Val-Asn, and with position 3 left as glutamate, changed to glycine, or changed to arginine. Folding the bacterial product gave very high yields of active protein, and the authors suggested the hydrophobic extension helps IGF-I fold correctly. In cells that secrete IGF-binding proteins, potency ranked as the arginine-3 extended form and des(1-3)IGF-I highest, then the glycine-3 form, then the plain extended form, then IGF-I. In chicken embryo fibroblasts, which secrete no detectable binding proteins, the arginine-3 extended form was less potent than IGF-I. Binding studies showed the gain in potency came from changed interaction with the binding proteins, not from better receptor binding.
Read with care: Cells in dishes. It establishes a mechanism and a manufacturing method, not a benefit in any animal or person.
Journal of Molecular Endocrinology · pubmed.ncbi.nlm.nih.gov
Safety findings
- No human safety data of any kind were found for IGF-1 LR3: no trial, no registered study, and no published case series. No animal toxicity studies (repeat-dose, genetic, reproductive or cancer) were found either. A 2021 anti-doping paper states it has never been approved for human use. Source: pubmed.ncbi.nlm.nih.gov
- Low blood sugar is the clearest measured hazard. In pigs, the analogue and its relatives lowered blood glucose 2 to 3 times more strongly than IGF-I at the lowest point, and produced roughly 4 to 8 times more total glucose suppression over four hours. Maximum falls were 4.8 mmol/L in pigs and 3.7 mmol/L in conscious marmoset monkeys. In beef heifers an 8-hour infusion lowered glucose and all measured plasma amino acids. Source: pubmed.ncbi.nlm.nih.gov
- For a different molecule: the current FDA label for mecasermin (Increlex), recombinant human IGF-1, warns of severe hypoglycaemia leading to hypoglycaemic seizures; intracranial hypertension with swelling of the optic nerve, visual changes, headache, nausea or vomiting; enlargement of lymphoid tissue such as tonsils and adenoids, with complications; slipped capital femoral epiphysis; worsening of existing scoliosis; allergic reactions including anaphylaxis requiring hospitalisation; and malignant neoplasia, with several cases observed in children treated with it. The label contraindicates it in children with cancer or a history of cancer, and in those whose growth plates have closed. Source: dailymed.nlm.nih.gov
- Association, not proven cause: in a pooled analysis of 17 prospective studies (4,790 breast cancers), women in the top fifth of their own natural IGF-1 levels had 28% higher odds of breast cancer. In 394,388 UK Biobank participants followed for a mean 6.9 years, higher IGF-1 was associated with modestly higher risk of thyroid (hazard ratio 1.18 per 5 nmol/L), colorectal (1.08), breast (1.11) and prostate cancer (1.08), and with lower risk of ovarian and liver cancer; those authors noted reverse causality could not be excluded. A genetic (Mendelian randomisation) study found support for a causal link only with colorectal cancer, and called the evidence for prostate, breast and other sites inconclusive. All of this concerns people's own IGF-1 levels, not anyone given an analogue. Source: pubmed.ncbi.nlm.nih.gov
3 more safety findings
- Product quality is a documented problem, not a hypothetical one. The Cologne anti-doping laboratory reported unpurified long-R3-IGF-1 among seized black-market products analysed in 2009. In a separate case report the same group identified the contents of a black-market injection vial as Long-R3-IGF-I carrying a six-histidine tag on its tail end, joined by Leu-Glu linker residues; they wrote that the effects of this tagged form in humans are unknown and that it was more likely a research by-product than anything intended for injection. A 2021 anti-doping paper found that black-market products often contained oxidised forms of the peptide. Source: pubmed.ncbi.nlm.nih.gov
- Giving the analogue changes the whole IGF system, not one value. In beef heifers the animals' own IGF-1 fell steeply during an 8-hour infusion, plasma IGF-2 fell about three times further than in controls, and a 31 to 32 kDa binding protein rose. In rats, both IGF-I and the analogue enlarged the gut substantially, and the organ-weight effects of IGF treatment were measurable within a week. Source: pubmed.ncbi.nlm.nih.gov
- Long-term exposure has been studied in one animal species only. The longest treatment found anywhere was seven months of intranasal dosing in mice, which improved body composition but did not preserve learning or memory. No longer or controlled exposure exists in any species, and none in people. Source: pubmed.ncbi.nlm.nih.gov
Rules and status
Not approved. IGF-1 LR3 is not an approved medicine in the United States and is not on any of FDA's pharmacy compounding lists. The only approved human IGF-1 product is a different molecule, plain recombinant human IGF-1 (mecasermin, Increlex), approved in August 2005 for one rare childhood growth disorder.
The full history, with dates
What is established: (1) No approval. A search of FDA's Drugs@FDA records found no approved product containing this analogue. The only mecasermin application is BLA 021839 (originally an NDA, deemed a biologics licence in March 2020), approved 30 August 2005, sponsor Ipsen, for plain recombinant human IGF-1 and not for this analogue. A 2021 anti-doping paper states the analogue has never been approved for human use. (2) Not on FDA's compounding lists. FDA's page 'Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks' (content current as of 22 April 2026) was read in full. Its Category 2 table lists 14 substances and its 'nominated but withdrawn' table lists 18; neither names IGF-1, IGF-1 LR3, Long R3 IGF-I, insulin-like growth factor or mecasermin. The closest entry is PEG-MGF (pegylated mechano growth factor), a different molecule, in the withdrawn table. So unlike BPC-157 or TB-500, this substance was never put into Category 2 and never nominated-and-withdrawn: it appears simply not to have been taken up in the 503A compounding process at all. (3) The HHS peptide notice does not reach it. On 30 October 2026 HHS published a Federal Register notice (91 FR 68526, docket HHS-OASH-2026-0496) announcing a draft, non-binding enforcement-discretion policy for 503A compounding with certain peptide bulk substances listed in an appendix. The notice itself was read in full and names no peptide, including no IGF-1 product; it says the policy is interim, does not bind HHS or the public, and may be revisited. Appendix A of the policy (on hhs.gov, read from an Internet Archive capture of 15 November 2026) names exactly six peptides: BPC-157, epitalon, KPV, MOTS-c, semax and TB-500. No IGF-1 product is among them. (4) What it is legitimately sold as. The substance has an established legitimate market as a cell-culture reagent, used in place of insulin when cells are grown to manufacture protein drugs; that use is documented in the peer-reviewed biotechnology literature. (5) Not formally established and not relied on here: no FDA briefing document, advisory committee discussion or Federal Register entry specific to this substance was found. Searches of FDA's own site surfaced no page addressing an insulin-like growth factor bulk substance. FDA's list of bulk drug substances nominated for 503A compounding by category (https://www.fda.gov/media/94155/download?attachment, updated 14 May 2026) was read in full: none of its three categories (Category 1, under evaluation; Category 2, significant safety risks; Category 3, nominated without adequate support) names IGF-1, insulin-like growth factor, mecasermin, Long R3 IGF-I or IGF-1 LR3. The nearest entry is 'Mechano growth factor (MGF)' in Category 3, a different molecule. So, as of 14 May 2026, no IGF-1 product appears in any 503A nomination category, in addition to being absent from the two tables on the safety-risk page.
Source: fda.gov (source dated 2026-04-22)
In sport: Prohibited at all times, in and out of competition. IGF-1 LR3 is not named by that name, but it is an analogue of IGF-1, and class S2 (Peptide hormones, growth factors, related substances, and mimetics), section S2.3 'Growth factors and growth factor modulators', names 'Insulin-like growth factor 1 (IGF-1, mecasermin) and its analogues' under the heading 'Including, but not limited to'. The wording is the same in the 2026 List (in force from 1 January 2026) and the 2027 List (published 21 September 2026, in force from 1 January 2027). The 2026 List states that all substances in S2 are non-Specified Substances. Independently, the 2021 anti-doping paper that developed a detection method for this exact analogue states that it is prohibited in sport. WADA
Claims and what the evidence supports
| What people say | What the evidence supports |
|---|---|
| IGF-1 LR3 is a longer-lasting version of IGF-1. | Measured in rats, it is the opposite: because the binding proteins act as a reservoir and the analogue escapes them, it is cleared from the blood far faster than IGF-I, about ten times faster, and circulates mostly as free peptide. In a rat study after a single injection the intact analogue was gone within about 4 hours while two other analogues were still detectable at 24 hours. Some secondary reviews state that it has a longer half-life; that claim was not supported by any primary measurement opened for this page. Source: pubmed.ncbi.nlm.nih.gov |
| It builds muscle. | No study in a person exists. In rats it raised whole-body nitrogen retention and muscle protein synthesis, and was several times more potent than IGF-I at doing so, but one of the Adelaide group's own studies in healthy female rats found the nitrogen retention could not be accounted for by the protein accretion their muscle measurements implied. In cattle the protein-sparing effect was reported as a tendency, not a clear result. Measurements that matter to a person, strength, performance or body composition, have never been made with it. Source: pubmed.ncbi.nlm.nih.gov |
| It is a proven research-grade pharmaceutical. | It is a reagent, not a medicine. The peer-reviewed use is as a growth factor added to cell cultures in place of insulin when companies grow cells to make protein drugs. Papers in the field call it an 'IGF-1 substitute'. No human trial and no approval exists. Source: pubmed.ncbi.nlm.nih.gov |
| It is essentially the same as the approved IGF-1 medicine, so its safety is known. | They are different molecules. The approved medicine, mecasermin, is the plain 70-amino-acid human protein; this is an 83-amino-acid variant altered specifically so that it escapes the control system that normally limits IGF-1's activity. The mecasermin label's warnings, severe hypoglycaemia with seizures, raised pressure around the brain, enlarged tonsils and adenoids, and malignant neoplasia, describe what raising IGF-1 signalling can do in children under medical supervision. They are a reason for caution, not safety data for this analogue. Source: dailymed.nlm.nih.gov |
| It is site-specific, or works only where you put it. | Nothing opened for this page supports that. In animals it acts systemically: it lowered blood sugar and plasma amino acids throughout the body in pigs and cattle, enlarged the gut by up to 60% in rats, and altered liver, spleen and heart weights. Rat clearance studies found the labelled analogue distributed to kidneys, ovaries and adrenal glands. Source: pubmed.ncbi.nlm.nih.gov |
| Low blood sugar is a minor, manageable side effect. | It is the best-documented effect of this class. In pigs the IGFBP-escaping variants produced roughly 4 to 8 times more total glucose suppression over four hours than IGF-I. For the approved human IGF-1 medicine, the label records severe hypoglycaemia leading to hypoglycaemic seizures, under supervision, with blood sugar monitoring and food timing built into its instructions. Source: pubmed.ncbi.nlm.nih.gov |
| Higher IGF-1 is simply good for you. | Observational studies point the other way for cancer. In a pooled analysis of 17 prospective studies, women with the highest natural IGF-1 levels had 28% higher odds of breast cancer. In 394,388 UK Biobank participants, higher IGF-1 was associated with modestly higher risk of thyroid, colorectal, breast and prostate cancer, and lower risk of ovarian and liver cancer. These are associations in people's own levels, not effects of taking anything, and a genetic study supported a causal reading only for colorectal cancer. Source: pubmed.ncbi.nlm.nih.gov |
| A vial labelled IGF-1 LR3 contains IGF-1 LR3. | Anti-doping laboratories have repeatedly found otherwise. Cologne reported unpurified long-R3-IGF-1 in seized products in 2009, and in a separate vial identified a version carrying a six-histidine laboratory purification tag whose effects in people are unknown. A 2021 study found oxidised forms common in black-market products, and recommended that testing look for them. Source: pubmed.ncbi.nlm.nih.gov |
What a genuine lab report should show
- The report should state which molecule was tested, by sequence or by residue count, not just the trade name. The analogue is 83 amino acids; plain IGF-1 is 70 amino acids and about 7649 Da. A mass result near 7.6 kDa on a vial labelled LR3 means the contents are ordinary IGF-1, not the analogue.
- Identity by mass spectrometry, with the measured mass compared against the expected mass for the 83-residue analogue. Anti-doping laboratories identify this substance by immunocapture followed by high-resolution mass spectrometry, on both intact and digested material.
- A specific check for oxidised forms. A 2021 anti-doping study found black-market products often contained oxidised peptide and recommended monitoring the single-oxidised form alongside the native one. A report that reports only a single purity figure will not show this.
- A specific check for purification tags and linker residues. One black-market vial was found to contain the analogue with a six-histidine tag and Leu-Glu linker on its tail end, a research-grade form whose effects in people are unknown. A tag changes the molecule and should appear in any honest identity test.
- Purity by HPLC (a method that separates a sample into its parts), reporting the largest single impurity and total impurities, not only a headline percentage. The Cologne laboratory's finding of 'unpurified' material in seized products is exactly what a real purity figure would expose.
- Because this material is made in bacteria or yeast, the report should cover residual host-cell protein and DNA, bacterial endotoxin, and aggregation (clumped peptide), none of which a simple identity-and-purity certificate shows.
- How much peptide is actually present (assay or net peptide content), since a vial's label weight usually includes salts and water.
- A lot or batch number matching the vial, the testing laboratory's name and the test date, so the report can be traced to the material in hand rather than to a different batch.
What is not known
- Whether this analogue has ever been given to a human being in a documented, measured way. No trial, registered study or case series was found. The only recorded human-directed products are black-market vials analysed by anti-doping laboratories.
- Its exact molecular mass and full amino acid sequence. No primary source opened for this page printed either. PubChem holds no compound record, only two supplier-deposited substance records with no structure. The 83-residue count is arithmetic: 70 residues of mature IGF-I (UniProt P05019) plus the 13-residue extension described by Francis and colleagues in 1992 and by a 2021 review. The approximately 9 kDa mass is an estimate and should not be published as a measured figure without a better source.
- A direct conflict about half-life. The Adelaide group's own measurements in rats found the analogue cleared from plasma about ten times faster than IGF-I, and a 2021 anti-doping study found the intact analogue undetectable in rats within about 4 hours. A 2021 review in Biomolecules states it has a considerably longer half-life. The primary measurements should be preferred, but the discrepancy is unresolved and the review's basis for the claim was not traced.
- Whether an IGF-1 product was ever nominated for the 503A list and dropped before the current documents. FDA's category list of 14 May 2026 (https://www.fda.gov/media/94155/download?attachment) names no IGF-1 product in any of its three categories, and the safety-risk page names none in Category 2 or in the withdrawn table, but these documents show only current status, not the full nomination history.
- What, if anything, happens with repeated long-term exposure. The only long treatment study found is seven months of intranasal dosing in male mice of one Alzheimer's model strain, and its functional outcome was negative. There are no repeat-dose toxicity, genetic toxicity, reproductive or cancer studies in any species.
- Whether the rat findings transfer to other species at all. Lord and colleagues found in 1994 that these IGFBP-escaping variants, which bind very weakly in rat plasma, bind noticeably in sheep, human, pig and chicken plasma. The thousandfold binding difference that explains the analogue's extra potency is a rat figure, and the margin in humans is unknown.
- Whether raised IGF-1 signalling from an outside source affects cancer risk. The epidemiology links people's own higher IGF-1 to modestly higher risk at several sites, and a genetic study supports a causal reading for colorectal cancer only. No study has looked at anyone given IGF-1 or an analogue outside approved medical use, and none has ruled the risk out.
Sources
All 37 sources
- Francis 1992: recombinant fusion protein analogues of IGF-I (the paper that introduced Long [Arg3]-IGF-I). pubmed.ncbi.nlm.nih.gov
- Tomas 1992: IGF-I and variants are anabolic in dexamethasone-treated rats. pubmed.ncbi.nlm.nih.gov
- Read 1992: IGF-I and N-terminally modified analogues induce gut growth in rats. pubmed.ncbi.nlm.nih.gov
- Tomas 1993: IGF-I and more potent variants restore growth of diabetic rats. pubmed.ncbi.nlm.nih.gov
- Tomas 1993: anabolic effects of IGF-I and an IGF-I variant in normal female rats. pubmed.ncbi.nlm.nih.gov
- Ballard 1993: IGFBP interactions, plasma clearance and in vivo activity of IGF analogues. pubmed.ncbi.nlm.nih.gov
- Bastian 1993: plasma clearance and tissue distribution of IGF-I and LR3IGF-I in pregnant rats. pubmed.ncbi.nlm.nih.gov
- Lord 1994: species differences in binding of IGF-I variants to plasma binding proteins (rat, sheep, pig, human, chicken). pubmed.ncbi.nlm.nih.gov
- Lord 1994: transfer of IGF-I and analogues from blood to intestine in lambs. pubmed.ncbi.nlm.nih.gov
- Bryant 1996: long-R3-IGF-I muteins designed to resist pepsin digestion. pubmed.ncbi.nlm.nih.gov
- Tomas 1997: IGF-I variants show more potent and prolonged hypoglycaemic action (pigs, marmosets). pubmed.ncbi.nlm.nih.gov
- Gajanandana 1998: ELISA that distinguishes LR3IGF-I from endogenous IGF-I and IGF-II. pubmed.ncbi.nlm.nih.gov
- Hill 1999: action of long(R3)-IGF-1 on protein metabolism in beef heifers. pubmed.ncbi.nlm.nih.gov
- Morris and Schmid 2000: insulin versus LongR3 in serum-free CHO cell cultures (biomanufacturing use). pubmed.ncbi.nlm.nih.gov
- Bieberich 2005: replacement of insulin by LongR3-IGF-1 in embryonic stem cell differentiation. pubmed.ncbi.nlm.nih.gov
- Kohler 2010: confiscated black market products analysed in Cologne in 2009 (unpurified long-R3-IGF-1). pubmed.ncbi.nlm.nih.gov
- Kohler 2010: detection of His-tagged Long-R3-IGF-I in a black market product. pubmed.ncbi.nlm.nih.gov
- Bailes and Soloviev 2021: IGF-1 and its monitoring in medical diagnostics and in sport (review; IGF-1 physiology, 13-residue extension, binding protein fractions). pmc.ncbi.nlm.nih.gov
- Mongongu 2021: detection of LongR3-IGF-I, Des(1-3)-IGF-I and R3-IGF-I for antidoping purposes (states never approved for human use). pubmed.ncbi.nlm.nih.gov
- Becker 2014: CHO transcriptome analysis of the IGF-1 substitute LongR3. pubmed.ncbi.nlm.nih.gov
- Lu 2023: recombinant expression of IGF-1 and LR3 IGF-1 in Pichia pastoris. pubmed.ncbi.nlm.nih.gov
- Engel 2025: intranasal long R3 IGF-1 in 5XFAD mice (seven months; failed to preserve cognition). pubmed.ncbi.nlm.nih.gov
- Endogenous Hormones and Breast Cancer Collaborative Group 2010: IGF1, IGFBP3 and breast cancer risk, pooled analysis of 17 prospective studies. pubmed.ncbi.nlm.nih.gov
- Knuppel 2020: circulating IGF-I and risk of 30 cancers in UK Biobank (394,388 participants). pubmed.ncbi.nlm.nih.gov
- Larsson 2020: IGF-1 and site-specific cancers, a Mendelian randomisation study. pubmed.ncbi.nlm.nih.gov
- UniProt P05019: human insulin-like growth factor 1 (mature chain residues 49-118, 70 amino acids). uniprot.org
- PubChem substance record SID 476298412: LONG R3 IGF-1 (human), CAS 143045-27-6 (supplier-deposited; no compound record exists). pubchem.ncbi.nlm.nih.gov
- DailyMed: current FDA label for INCRELEX (mecasermin), Eton Pharmaceuticals, published 20 May 2026, label revised 10/2025. dailymed.nlm.nih.gov
- FDA Drugs@FDA record for mecasermin: BLA 021839, approved 30 August 2005 (read through the openFDA API). api.fda.gov
- FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of 22 April 2026; no IGF-1 entry in either table). fda.gov
- FDA: Bulk drug substances used in compounding under section 503A (category definitions; content current as of 14 May 2026). fda.gov
- Federal Register, 30 October 2026 (91 FR 68526): HHS draft enforcement discretion policy for 503A compounding with certain peptide bulk drug substances (names no peptide). govinfo.gov
- ClinicalTrials.gov API search for Long R3 / LR3 IGF interventions: zero studies. clinicaltrials.gov
- WADA 2026 Prohibited List (S2.3 names IGF-1 and its analogues). wada-ama.org
- WADA 2027 Prohibited List, published 21 September 2026, in force 1 January 2027. wada-ama.org
- HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (the six peptides) and Appendix B (HHS reasoning); read from an Internet Archive capture of 15 November 2026. hhs.gov
- FDA: bulk drug substances nominated for use in compounding under section 503A, by category (updated 14 May 2026; no IGF-1 product in any category). fda.gov
Sources last checked 2026-11-18.
This page summarises published research and public records for education. It is not medical advice and it is not a guide to using any compound. If something here is wrong or out of date, tell us and we will correct it.